Drugs Affecting Lipid Metabolism

Dietary Advice for the Prevention of Arterial Thrombosis.- 27. Drugs Affecting High-Density Lipoprotein and Triglyceride Metabolism.- 28. Drugs Affecting Thrombosis and Atherosclerosis.- 29. Lipid Lowering: Progression and Regression of Atherosclerotic Lesions.- 30. Clinical Trials of Atherosclerosis Regression.- 31. Biochemical Mechanisms Associated with the Lipolytic Effects of Calcium Channel Blockers.- 32. Pravastatin Reduces Plasma Concentration of - More Electronegatively Charged LDL Subtraction in FH.- 33. Clinical Experience with Fluvastatin, the First Synthetic HMG-CoA Reductase Inhibitor.- 34. Secondary Prevention of Cardiovascular Disease: The Role of HMG-CoA Reductase Inhibitors.- 35. Combined Drug Treatment of Severe Hypercholesterolemia.- 36. Regression of Coronary Atherosclerosis by LDL-Apheresis.- 37. Partial Ileal Bypass - Results of the Program on the Surgical Control of the Hyperlipidemias (POSCH).- 38. Hypercholesterolemia: Negotiating the Issues.- 39. Antiatherosclerotic Drugs: - Critical Assessment.- 40. Experimental and Clinical Evidence for - Protective Role of High-Density Lipoprotein in Coronary Heart Disease.- 41. HDL as - Risk Factor for Coronary Heart Disease: An Update on the Helsinki Heart Study.- 42. Relationship of HDL Cholesterol to Incidence of Atherosclerotic Coronary Heart Disease: The PROCAM Experience.- 43. The Clinical Approach to the Patients with Low HDL and Elevated Plasma Triglyceride.- 44. Familial Lipoprotein Disorders in Patients with Premature Coronary Artery Disease.- 45. Efficacy of Fenofibrateon Plasma Cholesterol in Swine with Spontaneous Hypercholesterolemia.- 46. Lipoprotein Particles Heterogeneity: Clinical and Pharmacological Implication.- 47. Fibrinogen: Pathogenetical and Therapeutical Implications in Atherosclerosis.- 48. Regression and Decrease in Progression of Coronary Artery Disease Through Lipid-Lowering Therapy.- 49. Glycation and Oxidation of Proteins: - Role in the Pathogenesis of Atherosclerosis?.- 50. - Modern View of Atherogenesis.- 51. Defective Catabolism of Oxidized LDL by J774 Murine Macrophages.- 52. Analysis of Lipid vs. Non-Lipid Effect on Atherosclerosis Development.- 53. Atherogenicity of Triglyceride-Rich Lipoproteins: Cellular Aspects.- 54. Atherogenicity of Triglyceride-Rich Lipoproteins: Clinical Aspects.- 55. Factors Influencing the Altered Lipoprotein System in Hypertriglyceridemia.- 56. Effects of Fibrates on the Altered Lipoprotein System in Hypertriglyceridemia.- 57. Triglyceride-Rich Lipoproteins: Role in Atherogenesis and Haemostasis.- 58. The Role of Plasma Membrane Cholesterol Pools in the Regulation of Cellular Cholesterol Efflux.- 59. Kinetics of Exogenous Di-Linoleyl Phosphatidylcholine and Incorporation in Plasma and RBC Lipids in Man.- 60. Alimentary Lipemia and Phospholipids.